UK markets close in 3 hours 26 minutes

HAEMATO AG (HAEK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
26.60+0.30 (+1.14%)
As of 9:09AM CEST. Market open.
Full screen
Previous close26.30
Open26.60
Bid26.60 x N/A
Ask26.90 x N/A
Day's range26.60 - 26.60
52-week range18.50 - 37.00
Volume100
Avg. volume143
Market cap60.228M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Original-Research: HAEMATO AG (von First Berlin Equity Research GmbH)

    Original-Research: HAEMATO AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Update Empfehlung: Buy seit: 04.06.2021 Kursziel: 49 Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: 9 September 2019 Analyst: Ellis Acklin First Berlin Equity Research hat ein Research Update zu HAEMATO AG (ISIN: DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung

  • EQS Group

    HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.

    DGAP-News: HAEMATO AG / Key word(s): Quarter Results/Quarterly / Interim Statement31.05.2021 / 08:37 The issuer is solely responsible for the content of this announcement.______________________________________________________________________________Corporate News of HAEMATO AG: HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.Berlin, 31.05.2021 - HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22 % to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at all levels. The result from ordinary activities (EBITDA) rose by 196 % to EUR 2,823 thousand (previous year: EUR 954 thousand) and the operating result (EBIT) by 350% to EUR 2,428 thousand. Thus, after the first three months of the current year, EBIT already exceeds the figure for 2020 as a whole. One reason for the increase in earnings is the improvement in the gross margin, which has increased from 7.2 % (previous year) to 9.8 % in the first quarter of 2021."HAEMATO has streamlined its product portfolio in recent years and consistently focused on high-margin areas with sustainable growth potential. This is paying off more and more," says HAEMATO CEO Patrick Brenske. "Today, our growth drivers are special pharmaceuticals against chronic diseases and products around aesthetic medicine. For medical cannabis, demand clearly exceeds our supply and we are currently looking for additional suppliers."At the end of March 2021, the subsidiary HAEMATO PHARM GmbH received special approval from the Federal Institute for Drugs and Medical Devices (BfArM) for a Covid 19 antigen rapid test for self-testing by laypersons. In April and May 2021, a sales volume of almost EUR 25 million was already generated with the medical products from the "Diagnostics" segment, which will be positively reflected in the business figures for the second quarter of 2021. Medium-term demand for Covid 19 rapid tests depends largely on the further course of the pandemic, the vaccination rate and the national testing strategy in Germany.Due to the still ongoing Corona pandemic, HAEMATO AG will again make use of the option to invite shareholders to the company's Annual General Meeting scheduled for 13 July 2021 with a shortened notice period of 21 days.About HAEMATO:HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the trading of high-priced special pharmaceuticals (with a therapeutic focus on cancer, HIV, and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the field of "aesthetic medicine". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information at: www.haemato.ag.Contact:HAEMATO AG, Investor RelationsTelefon: +49 (0)30 897 30 86 70ir@haemato.ag31.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany Phone: +49 (0)30 897 30 86 70 Fax: +49 (0)30 897 30 86 79 E-mail: ir@haemato.ag Internet: www.haemato.ag ISIN: DE000A289VV1 WKN: A289VV Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 1202340 End of News DGAP News Service

  • EQS Group

    HAEMATO AG proposes dividend payment

    HAEMATO AG / Key word(s): Dividend/PayoutHAEMATO AG proposes dividend payment04-May-2021 / 15:10 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad hoc of HAEMATO AG: HAEMATO AG proposes dividend paymentThe Supervisory Board of HAEMATO AG approved the Executive Board's proposal for the appropriation of profits at today's balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting to be held on July 13, 2021.About HAEMATO:HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the trading of high-priced special pharmaceuticals (with a therapeutic focus on cancer, HIV and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the field of "aesthetic medicine".HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.Key figures of the HAEMATO AG share:Subscribed capital: EUR 5,299,307Listed share class: Ordinary bearer sharesISIN: DE000A289VV1WKN: A289VVStock exchange symbol: HAEKContact:HAEMATO AG, Investor RelationsTelefon: +49 (0)30 897 30 86 70ir@haemato.ag04-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany Phone: +49 (0)30 897 30 86 70 Fax: +49 (0)30 897 30 86 79 E-mail: ir@haemato.ag Internet: www.haemato.ag ISIN: DE000A289VV1 WKN: A289VV Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 1192406 End of Announcement DGAP News Service